|
| Press Releases |
|
 |
|
| Wednesday, March 11, 2026 |
|
|
Eisai to Present the Latest Data on Long-Term, Real-World Treatment with Lecanemab at the AD/PD(TM) 2026 Annual Meeting |
| Eisai Co., Ltd. announced today the company will present the latest findings on lecanemab, Eisai's anti-amyloid beta (Aβ) protofibril antibody for the treatment of Alzheimer's disease (AD), at the 20th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD(TM) 2026) from March 17-21, in Copenhagen, Denmark, and online. more info >> |
|
|
エーザイ、アルツハイマー・パーキンソン病学会（AD/PD 2026）において、レカネマブの長期実臨床治療をはじめとするアルツハイマー病の最新知見を発表 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫、以下エーザイ）は、2026 年 3 月17 日から 21 日にかけてデンマーク コペンハーゲンおよびバーチャルで開催される第 20 回アルツハイマー病・パーキンソン病学会（International Conference on Alzheimer's and Parkinson's Diseasesand related neurological disorders：AD/PD™ 2026）において、抗アミロイド β（Aβ）プロトフィブリル抗体レカネマブ（一般名、製品名「レケンビ®」）を含む、当社のアルツハイマー病（AD）領域の研究成果として、3 件の口頭発表を含む６件の発表を行うとともに、1 件のシンポジウムを主催することをお知らせします。 more info >> |
|
| Monday, March 2, 2026 |
|
|
WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC) |
| Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside of the United States and Canada) and Eisai (Headquarters: Tokyo, CEO: Haruo Naito) today announced the first presentation of results from the Phase 3 LITESPARK-011 trial evaluating the dual oral regimen of WELIREG(R) (belzutifan), Merck & Co., Inc., Rahway, NJ, USA's first-in-class oral hypoxiainducible factor-2 alpha (HIF-2a) inhibitor, plus LENVIMA(R) (lenvatinib), an orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, for the treatment of patients with advanced renal cell carcinoma (RCC) whose disease progressed on or after treatment with anti-programmed death receptor-1 (PD-1)/ programmed death-ligand 1 (PD-L1) therapy. more info >> |
|
|
エーザイとMerck & Co.,Inc.、「レンビマ(R)」（レンバチニブ）と「ウェリレグ(R)」（ベルズチファン）の併用療法が治療歴のある進行腎細胞がんにおいて、カボザンチニブと比較して、疾患進行または死亡のリスクを30％低減 |
| エーザイ株式会社とMerck & Co.,Inc., Rahway, NJ, USA（北米以外ではMSD）は、このたび、エーザイ創製の経口チロシンキナーゼ阻害剤「レンビマ(R)」（一般名：レンバチニブメシル酸塩）とMerck & Co., Inc., Rahway, NJ, USAのファースト・イン・クラスの経口低酸素誘導因子2アルファ（HIF-2α）阻害剤「ウェリレグ(R)」（一般名：ベルズチファン）の経口2剤による併用療法について、抗PD-1/L1療法治療中または治療後に疾患が増悪した進行腎細胞がん（RCC）の治療として評価した臨床第III相LITESPARK-011試験の結果を、2026年米国臨床腫瘍学会（ASCO）泌尿器がん（GU）シンポジウムにおいてLatebreaking口頭アブストラクト（抄録 #LBA417）として発表したことをお知らせします。 more info >> |
|
| Monday, February 16, 2026 |
|
|
エーザイ、新規オレキシン受容体作動薬 E2086 が日本において、ナルコレプシーを対象として、厚生労働省より希少疾病用医薬品に指定 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、このたび、自社創製の新規選択的オレキシン 2 受容体作動薬 E2086 について、予定される効能又は効果であるナルコレプシーを対象として、厚生労働省より希少疾病用医薬品（オーファンドラッグ）に指定されたことをお知らせします。 more info >> |
|
|
Ministry of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Novel Orexin Receptor Agonist E2086 for Narcolepsy |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it has received an orphan drug designation for its in-house discovered and developed novel selective orexin 2 receptor agonist E2086, with prospective indication for narcolepsy, from the Ministry of Health, Labour and Welfare (MHLW). more info >> |
|
| Tuesday, February 10, 2026 |
|
|
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Designated for Priority Review in China |
| Eisai Co., Ltd. and Biogen Inc. announced today that the Biologics License Application (BLA) for the subcutaneous formulation (subcutaneous autoinjector: SC-AI) of "LEQEMBI(R)" (generic name: lecanemab), an anti-amyloid beta (Aβ) protofibril antibody, which was accepted in January 2026, has been designated for Priority Review by the National Medical Products Administration (NMPA) of China. more info >> |
|
| Friday, February 6, 2026 |
|
|
Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Shanghai Henlius Biotech, Inc. (Headquarters: Shanghai, China, CEO: Jason Zhu, "Henlius") announced today the conclusion of an exclusive commercialization and co-exclusive development and manufacturing license agreement for the anti-PD-1 antibody serplulimab (generic name, marketed as HANSIZHUANG in China and Hetronifly(R) in the EU) in Japan. more info >> |
|
| Monday, January 26, 2026 |
|
|
FDA Accepts LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the U.S. Food and Drug Administration (FDA) has accepted for review Eisai's Supplemental Biologics License Application (sBLA) for lecanemab-irmb (U.S. brand name: LEQEMBI(R)) subcutaneous autoinjector (SC-AI), LEQEMBI IQLIK, as a weekly starting dose. more info >> |
|
|
エーザイとバイオジェン、抗 Aβ抗体レカネマブの皮下注射製剤「LEQEMBI(R) IQLIK(TM)」について、早期アルツハイマー病に対する初期療法からの投与を可能とする生物製剤承認一部変更申請が米国 FDA に受理され、優先審査に指定 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫、以下 エーザイ）とバイオジェン・インク（Nasdaq：BIIB、本社：米国マサチューセッツ州ケンブリッジ、CEO：Christopher A.Viehbacher、以下 バイオジェン）は、このたび、抗 Aβプロトフィブリル抗体レカネマブ（一般名）の皮下注オートインジェクター製剤（SC-AI）「LEQEMBI IQLIK」（レケンビ アイクリック）について、週 1 回投与による初期療法に関する生物製剤承認一部変更申請（sBLA）が米国食品医薬品局（FDA）に受理されたことをお知らせします。 more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
「星樞計劃」正式發布 鈞達股份多家下屬公司成為上海太空算力產業生態夥伴發起及首批單位
May 17, 2026 12:51 HKT/SGT
|
|
|
Shoucheng Holdings' First-Quarter Report Shows 18% Core Profit Growth and Sustained High Shareholder Returns
May 16, 2026 08:49 HKT/SGT
|
|
|
首程控股一季報核心利潤增長18% 高股東回報持續兌現
May 16, 2026 08:49 HKT/SGT
|
|
|
Tabor Redefines Anti-Drone Testing with Software-Defined SDR Platform
May 16, 2026 07:00 HKT/SGT
|
|
|
Substantial Shareholder Wei Fu Increases Shareholding in Everest Medicines Again, Marking His Second Share Purchase in 2026 and Demonstrating Long-term Confidence
May 15, 2026 22:20 HKT/SGT
|
|
|
NEC completes construction of approximately 2,250 km EMCS submarine cable linking Pacific island nations
May 15, 2026 17:36 JST
|
|
|
Fujitsu and Science Tokyo launch joint research hub for quantum hardware advancement and talent development
May 15, 2026 17:12 JST
|
|
|
Fujitsu and IBM Japan formalize collaboration in healthcare sector
May 15, 2026 16:42 JST
|
|
|
三菱重工機械システム、関越自動車道での交通混雑緩和キャンペーンに協力
May 15, 2026 15:30: JST
|
|
|
富士通と東京科学大学、量子ハードウェア技術の進展と人材育成に向けた共同研究を開始
May 15, 2026 15:30: JST
|
|
|
Toyota Launches All-New Land Cruiser "FJ" Series in Japan
May 15, 2026 15:24 JST
|
|
|
Mitsubishi Motors Signs Memorandum of Understanding with FPT Japan Holdings to Study Collaboration in Software and Digital Domain
May 15, 2026 15:10 JST
|
|
|
Your Go-To Travel Checklist for Smarter, Reward-Focused Travel Planning
May 15, 2026 14:00 HKT/SGT
|
|
|
NEC Launches Orbital Transfer Vehicle Development Project Aiming for Asia's First Vehicle Deployment through JAXA's Space Strategy Fund Program
May 15, 2026 14:55 JST
|
|
|
雲頂新耀主要股東傅唯再度增持 年內第二次加倉彰顯長期信心
May 15, 2026 13:00 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
